跳至主要内容
临床试验/2024-518738-97-00
2024-518738-97-00招募中2 期

Role of Vitamin D in GVHD prophylaxis in patients undergoing allogeneic transplantation stem cells. Pilot phase II study randomized open monocentric

Azienda Ospedaliero Universitaria Pisana1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年11月19日最近更新:
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
20
试验地点
1
主要终点
Reducing the severity of GVHD

研究概览

简要总结

Evaluation of the effectiveness of vitamin D on the degree si severity of acute and chronic GvHD

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Patients aged > 18 years. Male and female - Diagnosis of any oncohematologic disease with transplant indication, also allowed patients not in clinical response - Patients undergoing allogeneic stem cell transplantation regardless of conditioning regimen and HSC source - Ability to sign informed consent

排除标准

  • Transplantation from T-depleted or T-selected product; - Documented intolerance to the drug or any of its excipients; - Ongoing vitamin D therapy for any medical condition; -Hypercalcemia, hypercalciuria, kidney stones, renal failure; - Age < 18 years - Subjects who are not deemed legally capable of consent. - In the case of female: sex pregnancy and/or lactation.

结局指标

主要结局

Reducing the severity of GVHD

Reducing the severity of GVHD

次要结局

  • - Evaluation of circulating lymphocyte subpopulations on peripheral blood - Assessment of vitamin D receptor (VDR) surface expression and modulation in response to vitamin D treatment on lymphocyte subpopulations. - Evaluation of the soluble fraction of VDR on serum - post hoc evaluation of the role of polymorphisms (SNPs) of recipient and donor VDR on response to vitamin D therapy - collection of any adverse events brought about by cholecalciferol intake

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Clinical Trial Center

Scientific

Azienda Ospedaliero Universitaria Pisana

研究点 (1)

Loading locations...

相似试验